Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 8/20 | 0.48 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.48 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.36 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.36 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL764605 | 0.79 | GNAI3 (0.74) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL7399771 | 0.79 | GNAI3 (0.54) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL22223262 | 0.79 | GNAI3 (0.54) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL22223257 | 0.79 | GNAI3 (0.74) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL7407892 | 0.77 | GNAI3 (0.51) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL28360951 | 0.76 | GNAI3 (0.43) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL28364487 | 0.76 | GNAI3 (0.43) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL28364611 | 0.76 | GNAI3 (0.43) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL21103101 | 0.74 | EPHX2 (0.35) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL19851934 | 0.74 | ITGB3 (0.34) | GNAI3GNAO1GNAI1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-06-30 | — | — | US | disclosed |
| US-20210093725-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2021-04-01 | — | — | US | disclosed |
| WO-2020146521-A2 | RNAI AGENTS FOR INHIBITING EXPRESSION OF HIF-2 ALPHA (EPAS1), COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093725-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | ITGAV, ITGA5, ITGB5 | GNAI3 978/4885GNAO1 1033/4885GNAI1 1231/4885 |
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | EPAS1, HIF1AN, HIF1A | GNAI3 796/4885GNAO1 2098/4885GNAI1 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.